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Abstract: Epidemiologic analysis reveals that the mortality rate from ovarian cancer is 
continuously decreasing due to the improvement of surgery and chemotherapy. However, the 
prognosis of ovarian cancer patients is still unsatisfactory overall considering that only 30% of 
patients are alive after five years. In fact, although surgery and first-line systemic chemotherapy 
induces complete and partial response in up to 80% of patients with about a 25% pathological 
complete remission rate, recurrences occur in the majority of patients. The role of surgery in 
recurrent disease has been recently studied and many patients can receive an optimal secondary 
cytoreduction. Most of the recurrent patients are subject to a number of treatment regimens 
that, although palliative in nature, are also able to prolong survival. Important results have 
been obtained in particular in platinum-sensitive recurrent disease where a platinum-based 
chemotherapy is able to prolong progression-free survival and overall survival. Overall, our 
armamentarium for the treatment of progressive or recurrent ovarian cancer is significantly 
richer than in the past, and in many patients it is possible to achieve our goal of controlling the 
chronic behavior of the disease.
Keywords: ovarian cancer, chemotherapy
Introduction
The standard initial treatment of patients with advanced ovarian cancer is 
cytoreductive surgery, followed by combination chemotherapy with paclitaxel and 
a platinum compound.1,2 Despite the activity of this combination chemotherapy, 
which gives response rates up to 80%, the majority of patients die of recurrent 
disease.3 Therefore, a large proportion of patients are candidates for second-line 
therapy.
Patients who progress on first-line therapy or relapse within three months are 
considered to be refractory to a platinum re-treatment.4 Patients who respond to 
primary treatment and relapse within six months are considered platinum-resistant.4 
Patients who relapse more than six months after completion of initial therapy are 
characterized as platinum-sensitive.4 However, the sensitivity to platinum does not 
follow an exact time pattern, and independently from the cut-off time chosen, a 
longer platinum-free interval (PFI) increases the chances for a benefit by platinum 
re-challenge. This has been reported especially for PFI longer than 12 months.5,6 
Therefore, patients who relapse 6–12 months following the end of their initial 
regimen may benefit less and are classified as so-called partially sensitive. The latter Therapeutics and Clinical Risk Management 2009:5 422
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represents a challenging grey zone with respect to further use 
of platinum agents and platinum combination partners.
Treatment of platinum-refractory/
resistant ovarian cancer
Refractory/resistant ovarian cancers are not considered suit-
able for secondary surgical cytoreduction and their treatment 
is medical (Table 1). However, the value of a second-line 
therapy and its impact on survival is modest.4,7 Agents 
such as epirubicin8,9 and etoposide10 and the more recent 
active drugs topotecan,11 stealth liposomal doxorubicin,12,13 
and gemcitabine14 show response rates ranging from 10% 
to 25%, but lengthy remissions are infrequent.7 Thus, the 
treatment of these patients remains a challenge for the near 
future and there is a need for studies with new drugs. Some 
new biological agents have been also investigated in this 
setting; bevacizumab,15 erlotinib,16 and pazopanib17 have 
shown promising activity and are under investigation in 
phase III trials.
Pegylated liposomal doxorubicin (PLD) is considered 
the first choice single agent in these patients. The drug is a 
preparation of doxorubicin hydrocloridic acid in pegylated 
liposomes that confers a much longer half-life in blood and 
a different profile of toxicity than doxorubicin.18 The surface 
of the pegylated liposome is coated with methoxipolyeth-
ylene glycol polymers, which prevent liposomal detection 
and destruction by the reticuloendothelial system.19 In a 
phase III study, Gordon and colleagues12 compared PLD 
with topotecan in 481 patients with either platinum-sensitive 
(PFI  6 months) or platinum-refractory (PFI  6 months) 
recurrent ovarian cancer. Mature survival data demonstrated 
a significant benefit for PLD in the intent-to-treat population 
(hazard ratio [HR] = 1.23, 95% confidence interval [CI]: 
1.01–1.50; p = 0.038) which was particularly pronounced in 
patients with platinum-sensitive disease (HR = 1.432, 95% 
CI: 1.066–1.923; p = 0.017), while no significant difference 
was found in patients with platinum-refractory/resistant 
disease. The toxicity profile of liposomal doxorubicin was 
significantly better compared to topotecan, particularly in 
the hematological toxicity profile.
A phase III randomized trial (Multicenter Italian Trials in 
Ovarian cancer [MITO]-3) have recently compared PLD with 
gemcitabine in patients with PFI  12 months. The results 
demonstrated comparable efficacy and improved quality 
of life with PLD monotherapy compared with gemcitabine 
monotherapy in patients with recurrent ovarian cancer and 
a PFI of less than 12 months.20 No difference in survival 
between the two groups was shown in the subset of patients 
with a PFI of 6 months. However, a statistically significant 
improvement in survival was observed with PLD in those 
with PFI of 7–12 months (p = 0.013). Furthermore, patients 
in the PLD arm experienced statistically significantly higher 
global quality of life (QOL) scores at the first and second 
post-baseline QOL assessments.
In this subgroup of patients it has not been demonstrated 
that combination chemotherapy is better than single agents. 
The few studies performed showed increased toxicity with-
out any impact on survival. Recently a phase III study was 
performed comparing topotecan versus topotecan–etoposide 
versus topotecan–gemcitabine.21 None of the combinations 
improved progression-free survival (PFS) or overall survival 
compared to topotecan alone. Patients in the combination 
arms were at higher risk of hematological toxicity. Interest-
ing experiences have been published with the combination 
of stealth liposome doxorubicin with vinorelbine22 or gem-
citabine.23 Phase III data are needed, although activity and 
toxicity results seems very promising.
In this setting it is worthwhile to mention also the 
preliminary results of the study by Monk and colleagues24 
comparing PLD alone versus PLD plus trabectedin showing 
an advantage for the combination in terms of PFS. A subgroup 
analysis showed that the median PFS with PLD alone was 
7.5 months versus 9.2 months with PLD plus trabectedin 
(HR = 0.73, 95% CI: 0.56–0.95; p = 0.01) in patients with 
a PFI of 6–12 months. On the contrary, no difference was 
observed between single agent and combination therapy in 
patients with PFI lower than six months, also in this study. 
Thus, based on the available data, single agent chemotherapy 
remains the standard treatment in patients with resistant and 
refractory ovarian cancer.
Interesting data have been also published with single-agent 
weekly paclitaxel at the dose of 80 mg/m2 in platinum/
refractory ovarian cancer. In this study, an objective response 
rate of 20.9% was found and serious adverse events were 
very uncommon.25 Biological agents targeting specific cell 
factors have gained an important position in the treatment 
of many solid cancers. However, in ovarian cancer no new 
drug has reached the market up to now. Anti-endothelial 
growth factor (EGF) receptor antagonists have been 
studied in resistant ovarian cancer. Data with erlotinib16 
and gefitinib26 showing very low response rate, being in 
the range of 0%–6%. However, a certain number of disease 
stabilization in patients have been found, which justifies 
more studies in this setting of patients. The data on the use 
of the anti-vascular endothelial growth factor (anti-VEGF) 
antibody, bevacizumab, is noteworthy. The Gynecologic Therapeutics and Clinical Risk Management 2009:5 423
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Oncology Group have shown in a phase II study that the 
drug is able to induce a 18% response rate with 42% of 
patients progression-free at six months.15 Some caution 
in the treatment of heavily pre-treated patients has been 
claimed due to some cases of bowel perforation. However, 
the results obtained in second line prompted the International 
Cooperation in Gynecologic Oncology to promote two 
trials in first-line chemotherapy evaluating the addition of 
bevacizumab to standard carboplatin and paclitaxel.
An other interesting group of new molecular inhibitors 
is the family of poly (ADP-ribose) polymerase (PARP). In 
particular, the PARP-inhibitors AZB2281 has shown signi-
ficant anticancer activity on patients with BRCA-deficient 
ovarian cancer.27
Treatment of platinum-sensitive 
ovarian cancer with platinum-free 
interval 12 months
Many important studies have shown improvement in the 
outcome of fully platinum-sensitive recurrent ovarian cancer. 
Other studies will be completed very soon. One important 
question is when to initiate chemotherapy. In fact, the increase 
in CA 125 levels is often the first sign of recurrence without 
confirmatory imaging preceding symptoms and radiological 
signs of some months. There is no data indicating that early 
treatment during CA 125 increase improved survival com-
pared to delayed treatment during clinical or radiological 
relapse, although a trial by the European Organisation for 
Research and Treatment of Cancer (EORTC) is ongoing. Early 
treatment may negatively impact on QOL while the burden of 
disease may be too big if treatment start too late. A discussion 
with the patient is important in our view in order to tailor the 
start of treatment according to the patient’s expectations.
According to current dogma, sensitivity to a new 
treatment with platinum increases proportionally to PFI being 
at maximum after 18 months.4 As optimal cytoreduction is 
considered a major goal of treatment in the first-line setting, 
it has been proposed that a secondary cytoreduction may 
improve survival also in patients with sensitive recurrences. 
No prospective randomized data is available, but retrospective 
series suggest28 that when a cytoreduction with no residual 
disease is achieved, this can significantly impact on survival. 
The problem of patient selection for surgery is crucial 
and predictive scores have been recently proposed. The 
DESKTOP OVAR (Descriptive Evaluation of preoperative 
Table 1 Phase iii studies in platinum-resistant/refractory ovarian cancer
Study Treatment Objective response Progression-free 
survival (median)
Overall survival 
(median)
Gordon et al12 PLD 50 mg/m2 (n = 239)
Topotecan (1.5 mg/m2 daily for  
five consecutive days) (n = 235)
19.7%
17.0%  
(P = 0.390)
16.1 wk
17.0 wk  
(P = 0.095)
60 wk
56.7 wk
O’Byrne et al13 PLD 50 mg/m2 (n = 107)
Paclitaxel 175 mg/m2 (n = 107)
17.8%
22.4%  
(P = 0.34)
21.7 wk
22.4 wk  
(P = 0.15)
45.7 wk
56.1 wk  
(P = 0.44)
Ten Bokkel Huinink et al11 Topotecan 1.5 mg/m2 daily for 
five consecutive days (n = 112) 
Paclitaxel 175 mg/m2 (n = 114)
20.5%
13.2% 
(P = 0.138)
18.9 wk
14.7 wk 
(P = 0.08)
63.0 wk
53.0 wk 
(P = 0.44)
Topotecan 1.25 mg/m2 daily for  
five consecutive days (n = 178)
27.8% 7.0 month 17.2 month
Topotecan 1.0 mg/m2 daily for 
five consecutive days and oral 
etoposide 50 mg on days 6 to 
12 (n = 177) 
36.1% 7.8 month 17.8 month
Topotecan 0.5 mg/m2 daily for  
five consecutive days plus 
gemcitabine 800 mg/m2 on day 1 
and 600 mg/m2 on day 8 (n = 47)
31.6%  
(P = 0.368)
6.3 month 
(P = 0.3798)
15.2 month 
(P = 0.2344)
Ferrandina et al20 PLD 40 mg/m2 (n = 76)
Gemcitabin 1,000 mg/m2 on  
days 1, 8, and 15 (n = 77) 
16% 
29%
(P = 0.056)
16 wk 
20 wk
(P = 0.411)
56 wk 
51 wk
(P = 0.048)
Abbreviation: PLD, pegylated liposomal doxorubicin.Therapeutics and Clinical Risk Management 2009:5 424
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Selection KriTeria for OPerability in recurrent OVARian 
cancer) score considers three prognostic factors (platinum 
sensitivity, absence of residual disease at primary surgery, 
presence of ascites) was able to select patients in which there 
was a 67% probability of obtaining an optimal cytoreduction 
(no residual disease after surgery) for recurrent patients.29 
A prospective study (DESKTOP3) is ongoing in order to 
prospectively compare surgery vs no surgery in patients with 
recurrence of disease and a positive DESKTOP score.
Two large randomized studies in platinum-sensitive 
disease have demonstrated that the addition of a second drug 
to carboplatin improve the outcome of the patients.
The ICON4/AGO2.2 trial5 compared a platinum-based 
chemotherapy (70% carboplatin alone) with a carboplatin–
paclitaxel combination. In this study with 802 enrolled 
patients, there was an absolute difference in one-year PFS 
of 10% and in two-year survival of 7%. The combination 
induced an acceptable toxicity profile with neurotoxicity 
(20% G2–4) as the major complaint. This high rate of 
significant neurotoxicity can represent a limit since it has 
been shown that a significant proportion of recurrent patients 
have residual neurotoxicity from first-line treatment.30
Similar results has been obtained with the combination 
of carboplatin and gemcitabine versus carboplatin in 
patients with PFI  6 months.6 In this AGO study, the 
combination significantly improved PFS along with a better 
QOL. In particular, median PFS was 8.6 months (95% CI: 
7.9–9.7 months) for gemcitabine plus carboplatin compared 
to 5.8 months (95% CI: 5.2–7.1 months) for carboplatin 
alone (p = 0.0038). Toxicity was prevalently hematological, 
while neurotoxicity was of lower degree, and, as expected 
alopecia was not present. This study was not powered to 
show differences in overall survival, however PFS data were 
clearly in favor of the combination.
Due to these results the combinations of carboplatin–
paclitaxel and carboplatin–gemcitabine are in the market with 
the indication for treatment of platinum-sensitive recurrent 
ovarian cancer.
A phase II study from the French group, GINECO, has 
evaluated the combination of carboplatin and liposomal 
doxorubicin in platinum-sensitive recurrence. In this study, 
GINECO evaluated 30 mg/m2 of PLD every four weeks 
with carboplatin AUC5 in 104 patients who had received 
both a platinum and taxane as first-line (60%) or second-line 
(40%) therapy.30 The majority of patients (96%) had a PFI 
of  6 months; however, nearly half had a PFI of 12 months. 
Even with a significant proportion of patients having 
partially-platinum-sensitive disease, the overall response rate 
was 62%. Median PFS was 9.4 months, and median overall 
survival was 32 months.
Based on these data a randomized phase III trial 
CALYPSO (EORTC 55051), is underway and has fully 
accrued. CALYPSO compares PLD–carboplatin with 
paclitaxel–carboplatin using a 30 mg/m2 dose of PLD 
every four weeks. The primary endpoint of this trial is 
PFS. A total of 976 patients with recurrent ovarian cancer 
relapsing 6 months after first- or second-line platinum-
based therapy were enrolled. An interim safety analysis of 
the first 500 patients has been presented in abstract form.32 
Premature discontinuation of therapy due to toxicity 
appeared to be more frequent in the paclitaxel–carboplatin 
arm (36 patients [14%] vs. 15 patients [6%]). Treatment-
related serious adverse events were also more frequent in the 
paclitaxel–carboplatin arm (76 patients [30%] vs. 44 patients 
[18%]). These data reveal variations in the toxicity profile 
between the two combinations. The PLD–carboplatin 
treatment was associated with more grade 3/4 thrombocy-
topenia and more grade 2 mucositis and palmar-plantar 
erythrodysesthesia. In contrast, paclitaxel–carboplatin was 
associated with more grade 2 allergic reactions, alopecia, 
neuropathy, and arthralgia/myalgia. Final efficacy data are 
awaited to demonstrate whether carboplatin–PLD can be a 
tolerable alternative to paclitaxel–carboplatin in the setting 
of platinum-sensitive recurrent ovarian cancer.
Treatment of platinum-sensitive 
ovarian cancer with a platinum-free 
interval between 6 and 12 months
In partially platinum-sensitive disease (progression-free for 
6–12 months), the choice of treatment may or may not include 
a platinum agent. There is no randomized trial answering this 
question and thus there are only indirect evidences to discuss. 
When a platinum combination is chosen while waiting for 
the results of the CALYPSO, the treatments of choice are 
carboplatin–paclitaxel or carboplatin–gemcitabine. Phase III 
data reported for gemcitabine–carboplatin in this population 
demonstrated the utility of this combination.6 The median 
PFS with gemcitabine–carboplatin was 7.9 months versus 5.2 
months with carboplatin alone (HR = 0.69, 95% CI: 0.49–0.97; 
p = 0.03) in patients with a PFI of 6–12 months.
When a nonplatinum treatment is planned, PLD seems 
the treatment of choice based on the data of the Gordon study 
showing superiority for PLD over topotecan.12 Also, the 
MITO-3 data showed a survival advantage for PLD single agent 
over gemcitabine in patients between six and 12 months.20Therapeutics and Clinical Risk Management 2009:5 425
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In this setting, the preliminary results of the study 
comparing PLD alone versus PLD–trabectedin indicate that 
this scenario may quickly change. In this study, an advantage 
for the combination in terms of PFS was found in patients 
with recurrence between six and 12 months.24 These data may 
indicate that at least in partially platinum-sensitive patients 
a nonplatinum combination including trabectedin and PLD 
may have advantages compared to PLD alone. However, the 
question of platinum versus nonplatinum remains and should 
be answered by clinical trials.
In fact, utilizing nonplatinum agents in this setting to 
prolong the PFI is another issue of interest. In vitro and clinical 
data suggest that by using this strategy, platinum sensitivity may 
be restored.33–36 In fact, some preclinical studies suggest that 
some of the resistance mechanism of cisplatinium-resistance, 
such as the ability to repair DNA or the drug efflux systems, 
may be unstable over time.33,35,36 The topic is controversial 
since other studies suggest data adverse to this hypothesis.37 
A multicenter randomized phase III trial (MITO-8) is ongoing 
to evaluate whether utilizing PLD monotherapy to prolong 
the PFI in turn prolongs survival. Patients who progress for 
6–12 months following initial platinum-based therapy will be 
randomized to receive either PLD monotherapy followed by 
paclitaxel–carboplatin at the next progression or the reverse: 
paclitaxel–carboplatin and then PLD monotherapy at the second 
progression. The primary endpoint will be overall survival.
Conclusion
In the last fifteen years, several steps forward have been done in 
the field of medical treatment of ovarian cancer. In the setting 
of recurrence treatment, many drugs have shown significant 
activity and some trials showed that is possible to prolong 
survival, particularly in patients with platinum-sensitive 
recurrences. The correct sequence of the treatment and the best 
chemotherapy combinations are under investigation and the 
results of several phase III studies will be soon available. In 
the next few years we will know whether the new molecular 
inhibitors will be effective in ovarian cancer as it was proven in 
other malignancies. Phase III studies are ongoing worldwide to 
clarify whether the new biological agents will be able to change 
the medical treatment paradigm in recurrent ovarian cancer.
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